Group and the physicians do not last the time to explain it to them because they are paid not expressly for this service. That argument doubts naturally the entire idea of a market approach at the pharmaceutical market or at the health care markets generally uses on. Secondly these economists warned that purchase price calculation injures horizontal cheapness, because the poorer patients are robbed of the superior more probable by it more expensive products, than wealthier patients are. This argument however became with same Kraft at each possible defined contribution approach on health insurance and at any request, for to which the high Deductibles and reinsurance patients for each possible health service apply to up-succumb, as such preparations always the price rationing of the health care at the side edge the consequence has (to see it Reinhardt 1996). Much the controversy over purchase price calculation in particular the strong opposition of the pharmaceutical manufacturers to this approach, results from the definition „the equivalence “in the structure of the relevant „therapeutically equivalent groupings “that use up-requiring medicines. These groupings can be narrow or analyzed far. At the narrow end one can cover „therapeutically equivalent group of “drugs only drugs with the identical Active, chemical components, which limits inevitably the grouping on only generic drugs. At the other extreme very much on the forehead gerunzelt of research-created pharmaceutical manufacturers, can be defined „the therapeutically grouping equivalent “by the insurers, in order to include all products with the same therapeutic goal, including way patent and Aufpatent drugs with. Additional controversy results from the allotters of the purchase price “group of drugs equivalent within one therapeutically „. If only lowestpriced the drug in the group serves as the purchase price, all further products are exposed to the cost division of the patients, and its prices can be well down-pressed toward to lowreference price. However must be regarded thiswould as a market solution, rather as price control, because preferences and willingness of the patients had forced to pay the migration of prices toward to the purchase price. But, if a more expensive product, in the therapeutic grouping, would move away above somewhere in the middle when the purchase price were used, then the prices of the reduced in price products, including gene Eric, in the course of the time toward to the higher purchase price. It could lead high profit margins too much on noninnovative products, those not toward for the financing of R& contribute; Detailed discussion D. - Amore over purchase price calculation lies beyond the compass of this attempt (in this regard, you see 2003 to Kanavos and Reinhardt). If you are sufficient it to become finished in order to say, it is an efficient method of presenting market energy on the demand side of the use up-requiring medicines, which are taken off by sooner or later by the private health insurers to be probably covered the health insurance, and one, since they search, with at all-rising costs of health care.